This “Rheumatoid Arthritis - Pipeline Insight, 2020” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage
Rheumatoid Arthritis Understanding

Rheumatoid Arthritis: Overview

Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that immune system attacks healthy cells in body by mistake, causing inflammation (painful swelling) in the affected parts of the body. Rheumatoid arthritis mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. In a joint with RA, the lining of the joint becomes inflamed, causing damage to joint tissue. This tissue damage can cause long-lasting or chronic pain, unsteadiness (lack of balance), and deformity (misshapenness). Rheumatoid arthritis can also affect other tissues throughout the body and cause problems in organs such as the lungs, heart, and eyes.

Symptoms

Signs and symptoms of RA include:
Pain or aching in more than one joint
Stiffness in more than one joint
Tenderness and swelling in more than one joint
The same symptoms on both sides of the body (such as in both hands or both knees)
Weight loss
Fever
Fatigue or tiredness
Weakness
Diagnosis

Rheumatoid Arthritis is diagnosed by reviewing symptoms, conducting a physical examination, and doing X-rays and lab tests. It’s best to diagnose Rheumatoid Arthritis early - within 6 months of the onset of symptoms - so that people with the disease can begin treatment to slow or stop disease progression (for example, damage to joints). Diagnosis and effective treatments, particularly treatment to suppress or control inflammation, can help reduce the damaging effects of Rheumatoid Arthritis.

Treatment

Rheumatoid Arthritis can be effectively treated and managed with medication(s) and self-management strategies. Treatment for Rheumatoid Arthritis usually includes the use of medications that slow disease and prevent joint deformity, called disease-modifying antirheumatic drugs (DMARDs); biological response modifiers (biologicals) are medications that are an effective second-line treatment. In addition to medications, people can manage their Rheumatoid Arthritis with self-management strategies proven to reduce pain and disability, allowing them to pursue the activities important to them.

Rheumatoid Arthritis Emerging Drugs Chapters

This segment of the Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rheumatoid Arthritis Emerging Drugs

HB-adMSCs: Hope Biosciences

Hope Bio’s core technology lies in stem cell culture and banking. Mesenchymal stem cells are isolated from approximately one tablespoon of fat tissue, purified, and cultured with Hope Bio’s proprietary culture media, HB-101. HB-adMSCs are expanded to multiple passages and released at Passage 4 for therapeutic use. HB-adMSCs have already been used as a safe and effective treatment in a Phase I/IIa clinical trial for Rheumatoid Arthritis.

ABX464: Abivax

The Phase 2a study, ABX464-301, investigates the safety and tolerability of ABX464 in combination with methotrexate in patients with moderate-to-severe active Rheumatoid Arthritis. Patients enrolled in the study had an inadequate response to methotrexate or/and to one or more anti-tumor necrosis factor alpha (TNFα) therapies.

Rheumatoid Arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report.

Major Players in Rheumatoid Arthritis

There are approx. 50+ key companies which are developing the therapies for Rheumatoid Arthritis. The companies which have their Rheumatoid Arthritis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Gilead Sciences, Galapagos NV, Abivax, Viela Bio, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., Oscotec, Yungjin Pharm. Co., Ltd., AbbVie, Aclaris Therapeutics, Inc., Navidea Biopharmaceuticals, Bristol-Myers Squibb, SynAct Pharma Aps etc.

Phases

This report covers around 50+ products under different phases of clinical development like
Mid-stage products (Phase II and Phase I/II)
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Oral
Intramuscular
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
Small molecules
Monoclonal antibodies
Stem cell therapies
Immunotherapies
Peptide vaccines
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rheumatoid Arthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis.
August 2020: Gilead's rheumatoid arthritis medicine filgotinib, after cold shoulder from FDA, wins global-first nod in Japan. The U.S. agency raised concerns about sperm toxicity, especially for the higher, 200-mg dose.
Rheumatoid Arthritis Report Insights
Rheumatoid Arthritis Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Rheumatoid Arthritis Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
How many companies are developing Rheumatoid Arthritis drugs?
How many Rheumatoid Arthritis drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rheumatoid Arthritis?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rheumatoid Arthritis therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Rheumatoid Arthritis and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
Gilead Sciences
Galapagos
Abivax
Viela Bio
Jiangsu Alphamab Biopharmaceuticals Co.
Oscotec, Yungjin Pharm.
AbbVie, Aclaris Therapeutics
Navidea Biopharmaceuticals
Bristol-Myers Squibb
SynAct Pharma Aps
Key Products
HB-adMSCs
FURESTEM-RA Inj
Autologous adipose derived stem cells
ABX464
TJ003234
Umbilical cord mesenchymal stem cells
Ianalumab
GCK
hUC-MSC suspension
VIB4920
PF-06650833
GB224